Clinical Trial Update: A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating bevacizumab (Avastin) as anti-VEGF therapy for diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Jaeb Center for Health Research | Conditions: Diabetic Retinopathy | Phase 2 | Status: COMPLETED | Results posted: 2011-07-12